scholarly journals Graphene Oxide-Gold Star Construct on Triangular Electrodes for Alzheimer’s Disease Identification

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Wenlong Chang ◽  
Jing Zhao ◽  
Lu Liu ◽  
Xiaoming Xing ◽  
Chao Zhang ◽  
...  

Nanotechnology is playing a major role in the field of medical diagnosis, in particular with the biosensor and bioimaging. It improves the performance of the desired system dramatically by displaying higher selectivity and sensitivity. Carbon nanomaterial, gold nanostructure, magnetite nanoparticle, and silica substrate are the most popular nanomaterials greatly contributed to make the affordable and effective biosensor at low-cost. This research work is introducing a new sensing strategy with graphene oxide-constructed triangular electrodes to diagnose Alzheimer’s disease (AD). MicroRNA-137 (miRNA-137) was found as a suitable biomarker for AD, and the sensing method was established here to detect miRNA-137 on the complementary sequence. To enhance the immobilization of capture miRNA-137, gold nanostar (GNS) was conjugated with capture miRNA and immobilized on the GO-modified surface through an amine linker. This immobilization process enhanced the hybridization of the target and reaches the detection limit at 10 fM with the sensitivity of 1 fM on the linear curve with a regression coefficient of 0.9038. Further control sequences of miRNA-21 and single and triple base mismatched miRNA-137 did not show a significant response in current changes, indicating the specific miRNA-137 detection for diagnosing AD.

Drug Delivery ◽  
2021 ◽  
Vol 28 (1) ◽  
pp. 580-593
Author(s):  
Kaixuan Wang ◽  
Lingfeng Wang ◽  
Ling Chen ◽  
Chiwei Peng ◽  
Beijiao Luo ◽  
...  

2019 ◽  
Author(s):  
FR Farina ◽  
DD Emek-Savaş ◽  
L Rueda-Delgado ◽  
R Boyle ◽  
H Kiiski ◽  
...  

AbstractAlzheimer’s disease (AD) is a neurodegenerative disorder characterised by severe cognitive decline and loss of autonomy. AD is the leading cause of dementia. AD is preceded by mild cognitive impairment (MCI). By 2050, 68% of new dementia cases will occur in low- and middle-income countries. In the absence of objective biomarkers, psychological assessments are typically used to diagnose MCI and AD. However, these require specialist training and rely on subjective judgements. The need for low-cost, accessible and objective tools to aid AD and MCI diagnosis is therefore crucial. Electroencephalography (EEG) has potential as one such tool: it is relatively inexpensive (cf. magnetic resonance imaging; MRI) and is portable. In this study, we collected resting state EEG, structural MRI and rich neuropsychological data from older adults (55+ years) with AD, with MCI and from healthy controls (n~60 per group). Our goal was to evaluate the utility of EEG, relative to MRI, for the classification of MCI and AD. We also assessed the performance of combined EEG and behavioural (Mini-Mental State Examination; MMSE) and structural MRI classification models. Resting state EEG classified AD and HC participants with moderate accuracy (AROC=0.76), with lower accuracy when distinguishing MCI from HC participants (AROC=0.67). The addition of EEG data to MMSE scores had no additional value compared to MMSE alone. Structural MRI out-performed EEG (AD vs HC, AD vs MCI: AROCs=1.00; HC vs MCI: AROC=0.73). Resting state EEG does not appear to be a suitable tool for classifying AD. However, EEG classification accuracy was comparable to structural MRI when distinguishing MCI from healthy aging, although neither were sufficiently accurate to have clinical utility. This is the first direct comparison of EEG and MRI as classification tools in AD and MCI participants.


2021 ◽  
pp. 1-3
Author(s):  
Nicholas Clute-Reinig ◽  
Suman Jayadev ◽  
Kristoffer Rhoads ◽  
Anne-Laure Le Ny

Dementia and Alzheimer’s disease (AD) are global health crises, with most affected individuals living in low- or middle-income countries. While research into diagnostics and therapeutics remains focused exclusively on high-income populations, recent technological breakthroughs suggest that low-cost AD diagnostics may soon be possible. However, as this disease shifts onto those with the least financial and structural ability to shoulder its burden, it is incumbent on high-income countries to develop accessible AD healthcare. We argue that there is a scientific and ethical mandate to develop low-cost diagnostics that will not only benefit patients in low-and middle-income countries but the AD field as a whole.


RSC Advances ◽  
2017 ◽  
Vol 7 (88) ◽  
pp. 55709-55719 ◽  
Author(s):  
Mostafa Azimzadeh ◽  
Navid Nasirizadeh ◽  
Mahdi Rahaie ◽  
Hossein Naderi-Manesh

Serum miR-137 is quantified for the early detection of Alzheimer's disease using a electrochemically reduced graphene oxide and gold nanowire modified electrode.


2016 ◽  
Vol 27 (46) ◽  
pp. 465102 ◽  
Author(s):  
Islam Bogachan Tahirbegi ◽  
Wilmer Alfonso Pardo ◽  
Margarita Alvira ◽  
Mònica Mir ◽  
Josep Samitier

Alzheimer's disease (AD) is a degenerative brain disease, a common health problem in elderly pesople which causes decline in memory and affected on nerve cells. AD has different stages like mild congestive impairment (MIC) (early stage), moderate (middle stage), severe (late stage) it is essential to detect AD early in MIC, so that pre-emptive measures can be taken. Significant research was carried out over the past century to diagnose and detect this disease early. The objective of the article is provide a review evaluation and critical analysis of the recent research work done to early diagnosis of AD using Machine Learning Strategies.


2021 ◽  
Author(s):  
Sydney Y Schaefer ◽  
Michael Malek-Ahmadi ◽  
Andrew Hooyman ◽  
Jace B. King ◽  
Kevin Duff

Hippocampal atrophy is a widely used biomarker for Alzheimer's disease (AD), but the cost, time, and contraindications associated with magnetic resonance imaging (MRI) limit its use. Recent work has shown that a low-cost upper extremity motor task has potential in identifying AD risk. Fifty-four older adults (15 cognitively unimpaired, 24 amnestic Mild Cognitive Impairment, and 15 AD) completed six motor task trials and a structural MRI. Motor task acquisition significantly predicted bilateral hippocampal volume, controlling for age, sex, education, and memory. Thus, this motor task may be an affordable, non-invasive screen for AD risk and progression.


2021 ◽  
Author(s):  
Musfiquer Rhman ◽  
Farjana Rahman ◽  
Md. Mintu Hossain ◽  
Umma Habiba Emu ◽  
Khadija Akter ◽  
...  

2021 ◽  
pp. 1-7
Author(s):  
Sydney Y. Schaefer ◽  
Michael Malek-Ahmadi ◽  
Andrew Hooyman ◽  
Jace B. King ◽  
Kevin Duff

Hippocampal atrophy is a widely used biomarker for Alzheimer’s disease (AD), but the cost, time, and contraindications associated with magnetic resonance imaging (MRI) limit its use. Recent work has shown that a low-cost upper extremity motor task has potential in identifying AD risk. Fifty-four older adults (15 cognitively unimpaired, 24 amnestic mild cognitive impairment, and 15 AD) completed six motor task trials and a structural MRI. Several measures of motor task performance significantly predicted bilateral hippocampal volume, controlling for age, sex, education, and memory. Thus, this motor task may be an affordable, non-invasive screen for AD risk and progression.


The Analyst ◽  
2018 ◽  
Vol 143 (24) ◽  
pp. 5959-5964 ◽  
Author(s):  
Maria Paraskevaidi ◽  
Camilo L. M. Morais ◽  
Daniel L. D. Freitas ◽  
Kássio M. G. Lima ◽  
David M. A. Mann ◽  
...  

Plasma samples deposited on low-E slides were analysed in transmission mode by using a FT-NIR spectrometer in order to detect Alzheimer's disease using computer-based methods.


Sign in / Sign up

Export Citation Format

Share Document